Market closed · Next open: Monday 9:30 AM ET
Last update: Oct 16, 2026, 6:20 PM ET
Tempus AI, Inc.
$64.72▼ 9.01% today
Market Closed

Why Tempus AI, Inc. (TEM) stock moved

Updated Oct 17, 2026

Tempus AI, Inc. (TEM) shares tumbled 9.0% to $64.72 as of October 17, 2026, a significant decline from the prior close of $71.13. BestStocks flagged the session as a major change for TEM. The move is tied to price move down. Below, we break down what changed for TEM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

TEM fell 9.0% to $64.72

TEM tumbled 9.0% in its latest session, moving from $71.13 to $64.72.

Material / EarningsLow confidence
Rel. volume
1.0×
Normal
Vs peers
—
No comparable peers
Market cap
$11.4B
NASDAQ
Analyst target
$73
+12.2% vs price
Price chart
Sep 16 – Oct 16
ENENEVVNNVE$65$75$85Sep 16Sep 24Oct 1Oct 9Oct 16
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Tempus AI, Inc. investors

For Tempus AI, Inc. investors, the recent signals add up to a strong bearish shift. Weighing against that: Material negative event; Sharp 9.0% decline — elevated risk. Wall Street's consensus price target sits at $72.60, implying +12.2% upside from $64.72. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (59/100). With earnings roughly 16 days out, the next report is the most likely near-term test of the move.

TEM price reaction

TEM last traded at $64.72, down $6.41 (-9.01%) from the previous close of $71.13. The session traded on 1.0× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $64.72 and $85.08, and it currently sits about 0% of the way up that band.

Bullish and bearish analyst opinions on Tempus AI, Inc. (TEM)

The consensus analyst price target on Tempus AI, Inc. (TEM) is $72.60, 12.2% above the recent $64.72. Over the past 90 days analysts logged 1 upgrade, 12 maintains, and 0 downgrades. Here is how the bullish and bearish cases on TEM line up.

The bullish case

  • Wall Street's consensus price target of $72.60 implies +12.2% upside from $64.72.
  • The Street's most bullish target is $92.00 (+42.2%).
  • 1 analyst upgrade in the past 90 days, most recently Piper Sandler to Overweight (2026-09-01).

The bearish case

  • The most bearish analyst target is $50.00 (-22.7%).
  • Material negative event.
  • Sharp 9.0% decline — elevated risk.
  • Tempus AI fell 6.11% to $76.90 despite announcing 13 abstracts accepted for presentation at the European Society for Medical Oncology Congress 2026 (Business Wire).
  • Tempus AI, Inc. (TEM) moved -7.74% from $52.47 to $48.41 on 2026-07-20.
Bull vs bear balanceStrong Bearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Oct 17, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $73+12.2%
↑ 1 upgrades= 12 maintains
JP Morgan maintained Neutral · 2026-10-14
SEC filings watch
10-Q2026-07-30
Quarterly financial results
medium
8-K2026-07-30
Material event — review for impact
high
8-K2026-07-20
Material event — review for impact
high
8-K2026-07-20
Material event — review for impact
high
Peer context
TEM-9.0%

Previous notable changes for TEM

News2026-10-15+4.1%
Tempus AI scheduled to release Q3 2026 financial results on November 2, 2026.
Material / Earnings2026-10-15+4.1%
Tempus AI, Inc. (TEM) moved +9.26% from $65.10 to $71.13 on 2026-10-15 following a price target hike from JPMorgan Chase & Co. on October 14, 2026. The move was also supported by the launch of GenomeNext™, a whole-genome sequencing test by Tempus subsidiary Ambry Genetics for rare disease diagnosis, and continued momentum from its multi-year collaboration expansion with Moderna and Merck for individualized cancer therapies.
News2026-10-13+0.3%
Ambry Genetics, Tempus subsidiary, launches GenomeNext whole genome sequencing test for rare disease diagnosis.
Material / Earnings2026-10-06-13.8%
Tempus AI, Inc. (TEM) moved -15.28% from $84.97 to $71.98 on 2026-10-06 on volume 2.6x the 5-day average. We checked news, earnings, analyst updates, filings, and corporate actions. The only company-specific event found was an announcement that Tempus AI launched FDA-cleared AI-ECG tools to expand its cardiovascular diagnostic portfolio—a product expansion, not an earnings miss or negative catalyst.
Upcoming catalysts & outlook
Next earnings
2026-11-02 (est.)
in 16 days
Earnings Release
2026-11-02
High impact
Thesis shift
Strong Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about TEM

Why did Tempus AI, Inc. (TEM) stock move?

TEM tumbled 9.0% to $64.72. No single company-specific catalyst was confirmed during the move window, and it looks technical.

How much did TEM stock fall?

TEM lost 9.01% ($6.41) versus the prior close of $71.13, last trading at $64.72 on 1.0× average volume.

When is Tempus AI, Inc.'s next earnings date?

TEM's next earnings report is estimated for 2026-11-02 — about 16 days away.

What is the analyst price target for TEM?

The consensus analyst price target for TEM is $72.60, about 12.2% above the current $64.72. Over the past 90 days, analysts recorded 1 upgrade, 12 maintains, and 0 downgrades.

How BestStocks tracks TEM

This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for TEM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 17, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesAnalyst ratings & price targets (FMP)SEC EDGAR filingsEarnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.